Clinical Trial Update: Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety study assessing the clinical and immune effects of a PDE-4 inhibitor in discoid lupus erythematosus has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Discoid Lupus Erythematosus

Snippet

Sponsor: NYU Langone Health | Conditions: Discoid Lupus Erythematosus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-03-03